A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.

Eitemau Tebyg

• Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer
  gan: Irlam-Jones, J, et al.
  Cyhoeddwyd: (2016)
• A gene signature for selecting benefit from hypoxia modification of radiotherapy for high risk bladder cancer patients
  gan: Yang, L, et al.
  Cyhoeddwyd: (2017)
• Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial
  gan: Eustace, A, et al.
  Cyhoeddwyd: (2013)
• Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
  gan: Eustace, A, et al.
  Cyhoeddwyd: (2013)
• Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma.
  gan: Betts, G, et al.
  Cyhoeddwyd: (2013)